Literature DB >> 16046234

Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.

Patricia Disperati1, Christine V Ichim, Douglas Tkachuk, Kathy Chun, Andre C Schuh, Richard A Wells.   

Abstract

Myelodysplastic syndrome (MDS) comprises a group of clonal haematopoietic disorders characterized by peripheral blood cytopenias, bone marrow hypercellularity, and abnormal blood cell differentiation. Approximately 30% of cases of MDS eventually progress to acute myelogenous leukemia (AML), while progression of MDS into acute lymphoblastic leukemia (ALL) is rare. In this report, we describe a case of MDS that progressed to ALL, and review the 21 previously reported cases of MDS to ALL transformation. We review the cancer stem cell model and its application to these disorders, and discuss the implications of the rarity of transformation of MDS to ALL for the biology of MDS and the pathogenesis of ALL.

Entities:  

Mesh:

Year:  2005        PMID: 16046234     DOI: 10.1016/j.leukres.2005.06.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  21 in total

1.  Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Authors:  M V Ramana Reddy; Padmavathi Venkatapuram; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Kimberly A Robell; Balaiah Akula; Benjamin S Hoffman; E Premkumar Reddy
Journal:  J Med Chem       Date:  2011-08-17       Impact factor: 7.446

Review 2.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

3.  Obesity over the life course and risk of acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Jenny N Poynter; Michaela Richardson; Cindy K Blair; Michelle A Roesler; Betsy A Hirsch; Phuong Nguyen; Adina Cioc; Erica Warlick; James R Cerhan; Julie A Ross
Journal:  Cancer Epidemiol       Date:  2015-12-22       Impact factor: 2.984

4.  RARS with fibrosis and del(20q) transformed into ALL.

Authors:  Sandra S Rohr; Luís Arthur Flores Pelloso; Aline dos Santos Borgo; João Garibaldi de Rezende; Maria Regina Regis Silva; Mihoko Yamamoto; Maria de Lourdes L F Chauffaille
Journal:  Med Oncol       Date:  2012-07-04       Impact factor: 3.064

5.  Alcohol use is not a significant contributor to myelodysplastic syndromes.

Authors:  Elizabeth A Duffy; Phuong L Nguyen; Adina Cioc; Erica Warlick; Michelle A Roesler; Jenny N Poynter
Journal:  Cancer Causes Control       Date:  2020-04-13       Impact factor: 2.506

6.  A rare case of transformation of childhood myelodysplastic syndrome to acute lymphoblastic leukemia.

Authors:  Young Rae Koh; Eun Hae Cho; Seong Shik Park; Mi Young Park; Sun Min Lee; In Suk Kim; Eun Yup Lee
Journal:  Ann Lab Med       Date:  2013-02-21       Impact factor: 3.464

7.  c-myb hyperactivity leads to myeloid and lymphoid malignancies in zebrafish.

Authors:  W Liu; M Wu; Z Huang; J Lian; J Chen; T Wang; A Y H Leung; Y Liao; Z Zhang; Q Liu; K Yen; S Lin; L I Zon; Z Wen; Y Zhang; W Zhang
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

8.  A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement.

Authors:  Chul Won Choi; Yang Jo Chung; Christopher Slape; Peter D Aplan
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

9.  T cells of patients with myelodysplastic syndrome are frequently derived from the malignant clone.

Authors:  Suzanne M Vercauteren; Daniel T Starczynowski; Sandy Sung; Kelly McNeil; Chris Salski; Clara-Lynn Jensen; Helene Bruyere; Wan L Lam; Aly Karsan
Journal:  Br J Haematol       Date:  2012-02       Impact factor: 6.998

10.  Myelodysplastic syndrome transformed into B-lineage acute lymphoblastic leukemia: A case report.

Authors:  Ye-Jing Zhu; Xiang-Yu Ma; Yun-Liang Hao; Yun Guan
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.